CASE REPORT
Published on 16 Sep 2022
Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report

doi 10.3389/fonc.2022.912490
- 1,988 views
- 9 citations